In both the Easyhaler DPI and Evohaler pMDI cohorts, 98.3% of patients with asthma recovered FEV1 to at least -10% of baseline after their last treatment post MC test. Investigators sought to ...
Mylan becomes the first company to market a generic version of the UK's number one prescribed long-acting beta2-agonist + inhaled corticosteroid pressurized metered-dose inhaler asthma therapy[1],[2] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results